摘要
目的探讨吉西他滨联合顺铂(GP)与紫杉醇联合顺铂(TP)方案治疗晚期肺鳞癌的疗效及不良反应。方法选取晚期肺鳞癌患者91例,其中接受GP方案治疗患者47例(GP组),TP方案治疗患者44例(TP组),评价两组患者临床疗效及不良反应。结果治疗2个周期后,GP组近期有效率为40.43%,高于TP组的20.45%,两组比较差异有统计学意义(P﹤0.05);GP组疾病控制率为85.11%,虽高于TP组的77.27%,但差异无统计学意义(P﹥0.05);GP组和TP组患者中位生存时间为9个月和8个月,1年生存率分别为28.00%和24.00%,2年生存率分别为12.50%和12.00%,两组比较差异无统计学意义(P﹥0.05);两组患者于第1次和第3次化疗前CEA、CA125和CA50比较差异无统计学意义(P﹥0.05),第3次化疗前CEA、CA125和CA50均较第1次化疗前有所降低(P﹤0.05);两组患者主要不良反应为骨髓抑制、肝肾功能异常、脱发等,且近期不良反应严重程度相似,其中TP组脱发的严重程度高于GP组,差异有统计学意义(P﹤0.01)。结论 GP与TP方案治疗晚期肺鳞癌均有较好的临床疗效,且化疗不良反应相似,均可耐受。
Objective To investigate the efficacy of gemcitabine plus cisplatin （GP） and paclitaxel plus cisplatin （TP） in the treatment of advanced lung squamous cell carcinoma. Method 91 cases of advanced lung squamous cell carcino-ma were enrolled in this study, in which 47 patients were given GP regimen （GP group）, and 44 patients were adminis-tered with TP regimen （TP group）, and the clinical efficacy and adverse reactions of the two groups were compared. Re-sult After two cycles of treatment, the short-term response rate of GP group was 40.43%, which was significantly higher than that of TP group at 20.45%（P〈0.05）;the disease control rate was statistically similar between GP group at 85.11%and TP group at 77.27% （P〉0.05）; as for survival in GP the TP group, the median survival time were 9 months and 8 months, the 1 year survival rates were 28.00%and 24.00%, the 2 year survival rates were 12.50%and 12.00%, all were similar between the two groups （P〉0.05）;the CEA, CA125 and CA50 levels were comparable in both groups before the first and third chemotherapy （P〉0.05）, while those measures before third chemotherapy were decreased as compared with that before first chemotherapy （P〈0.05）;the major adverse reactions were myelosuppression, liver and kidney dysfunc-tion, and alopecia, etc, and the recent adverse reactions were similar in severity, except the severity of alopecia which was significantly higher in TP group （P〈0.01）. Conclusion GP and TP regimen were both effective in the treatment of ad-vanced lung squamous cell carcinoma, with similar yet tolerable adverse reactions.
出处
《癌症进展》
2016年第4期384-386,389,共4页
Oncology Progress
关键词
肺鳞癌
GP方案
TP方案
临床疗效
不良反应
lung squamous cell carcinoma
GP
TP
clinical efficacy
adverse reaction
